Rhinophototherapy in persistent allergic rhinitis
Previous published results have revealed that Rhinolight® intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergi...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2017
|
| Sorozat: | EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
274 No. 3 |
| doi: | 10.1007/s00405-016-4358-x |
| mtmt: | 3196314 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/11103 |
| LEADER | 02428nab a2200313 i 4500 | ||
|---|---|---|---|
| 001 | publ11103 | ||
| 005 | 20191022130424.0 | ||
| 008 | 170328s2017 hu o 0|| zxx d | ||
| 022 | |a 0937-4477 | ||
| 024 | 7 | |a 10.1007/s00405-016-4358-x |2 doi | |
| 024 | 7 | |a 3196314 |2 mtmt | |
| 040 | |a SZTE Publicatio Repozitórium |b hun | ||
| 041 | |a zxx | ||
| 100 | 1 | |a Bella Zsolt | |
| 245 | 1 | 0 | |a Rhinophototherapy in persistent allergic rhinitis |h [elektronikus dokumentum] / |c Bella Zsolt |
| 260 | |c 2017 | ||
| 300 | |a 1543-1550 | ||
| 490 | 0 | |a EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY |v 274 No. 3 | |
| 520 | 3 | |a Previous published results have revealed that Rhinolight® intranasal phototherapy is safe and effective in intermittent allergic rhinitis. The present objective was to assess whether phototherapy is also safe and effective in persistent allergic rhinitis. Thirty-four patients with persistent allergic rhinitis were randomized into two groups; twenty-five subjects completed the study. The Rhinolight® group was treated with a combination of UV-B, UV-A, and high-intensity visible light, while the placebo group received low-intensity visible white light intranasal phototherapy on a total of 13 occasions in 6 weeks. The assessment was based on the diary of symptoms, nasal inspiratory peak flow, quantitative smell threshold, mucociliary transport function, and ICAM-1 expression of the epithelial cells. All nasal symptom scores and nasal inspiratory peak flow measurements improved significantly in the Rhinolight® group relative to the placebo group and this finding persisted after 4 weeks of follow-up. The smell and mucociliary functions did not change significantly in either group. The number of ICAM-1 positive cells decreased non-significantly in the Rhinolight® group. No severe side-effects were reported during the treatment period. These results suggest that Rhinolight® treatment is safe and effective in persistent allergic rhinitis. © 2016, Springer-Verlag Berlin Heidelberg. | |
| 700 | 0 | 1 | |a Kiricsi Ágnes |e aut |
| 700 | 0 | 2 | |a Viharosné Dósa-Rácz Éva |e aut |
| 700 | 0 | 2 | |a Dallos Attila |e aut |
| 700 | 0 | 2 | |a Perényi Ádám |e aut |
| 700 | 0 | 2 | |a Kiss Mária |e aut |
| 700 | 0 | 2 | |a Koreck Andrea Ildikó |e aut |
| 700 | 0 | 2 | |a Kemény Lajos |e aut |
| 700 | 0 | 2 | |a Jóri József |e aut |
| 700 | 0 | 2 | |a Rovó László |e aut |
| 856 | 4 | 0 | |u http://publicatio.bibl.u-szeged.hu/11103/1/Rhinophototherapy_..2017_u.pdf |z Dokumentum-elérés |